Company Overview and News

0
Cummins India Limited - Book Closure

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

4
Tata Motors, Mahindra top RD spenders in auto industry

2018-07-15 moneycontrol
Homegrown companies Tata Motors and Mahindra & Mahindra were the biggest spenders on research and development in 2016-17 among 25 automakers in India which together invested Rs 6,344 crore, latest industry data showed.
BAJAJ-AUTO 532977 505200 CMQMY CUMMINSIND HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500033 ASHOKLEY ECQRY FORCEMOT MRZUY AKLD 532500 500182 500480 MARUTI 7269 501455 HRTQY GREAVESCOT AKLS TTM

0
Cummins India Limited - Updates

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

0
Cummins India Limited - Shareholders meeting

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

0
Cummins India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

2
Cummins India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

21
Market Live: Nifty struggles below 10,800; Jhunjhunwala says 2018 is the year of consolidation

2018-06-21 moneycontrol
KNR in focus: In a clarification note to the exchanges regarding "Promoters of Company taking large interest free loan from the Company", KNR Constructions said the promoters have extended unsecured loan of Rs 214.08 crore to the company, at the interest rate of 8.45 percent per annum to defray the term loan of one of the SPV. "There are no loans and advances given by the Company to promoters."
OPTOCIRCUI 500325 RELIANCE IDBI 539254 533155 JUBLFOOD 511288 CMQMY RIGD JBLWY CUMMINSIND HDFCBANK 500378 RLNIY SBAZ ADANITRANS GRUH INDIGO 500116 534690 IBN GRHFY 532942 539207 539448 KNRCON 500480 ICICIBANK LAKSHVILAS HDB 532174 500180 JINDALSAW 532391 MANPASAND

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...